Concepedia

Publication | Open Access

Effect of 26 Weeks of Liraglutide Treatment on Coronary Artery Inflammation in Type 2 Diabetes Quantified by [64Cu]Cu-DOTATATE PET/CT: Results from the LIRAFLAME Trial

DOIFull Paper Access

38

Citations

29

References

2021

Year

Jacob K. Jensen, Emilie H. Zobel, Bernt Johan von Scholten, Viktor Rotbain Curovic, Tine W. Hansen, Peter Rossing, R Ripa
Frontiers in Endocrinology

Abstract

Liraglutide treatment for 26-weeks caused a significant reduction in [<sup>64</sup>Cu]Cu-DOTATATE uptake in the coronary arteries whereas this was not seen in the placebo treated group. In addition, [<sup>64</sup>Cu]Cu-DOTATATE PET/CT as a marker of coronary inflammation correlated with the systemic inflammation marker hs-CRP.

References

YearCitations

Page 1